Table 1. Patient demographic and disease characteristics.

Characteristic	Patients in primary analysis; n=104 n (%) (unless noted)
Age
Median, years (range)	65 (36-83)
36-54 years	22 (21.2%)
55-69 years	49 (47.1%)
70-83 years	33 (31.7%)
Sex
Male	83 (79.8%)
Female	21 (20.2%)
Primary site
Mid-Thoracic Esophagus	11 (10.6%)
Lower Thoracic Esophagus (Excludes GE Junction)	38 (36.5%)
Gastro-Esophageal Junction	49 (47.1%)
Esophagus, NOS	4 (3.9%)
Other Primary Site	2 (1.9%)
Clinical Staging for Esophageal Cancer
Stage 0	9 (9.4%)
Stage I	21 (21.9%)
Stage IIa	22 (22.9%)
Stage IIb	10 (10.4%)
Stage III	32 (33.3%)
Unknown Stage	2 (2.1%)
Regional Lymph Node Involvement
Not Involved or No Clinical Evidence of Involvement	60 (57.7%)
Involved	43 (41.3%)
Unknown	1 (1.0%)
Neoadjuvant therapy	35 (33.7%)
Radiation Therapy	27 (26.0%)
Chemotherapy	35 (33.7%)
ECOG performance status*
0	71 (68.3%)
1	29 (27.9%)
2	4 (3.8%)

^*ECOG performance status—0: fully active, able to carry on all pre-disease performance without restriction; 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; and 2: ambulatory and capable of self-care but unable to carry out any work activity.

GE indicates gastroesophageal; NOS, not otherwise specified.